Mesoblast Limited develops allogeneic cellular medicines for severe inflammatory conditions through a proprietary mesenchymal lineage cell therapy platform. Its commercial and pipeline updates center on Ryoncil® (remestemcel-L-rknd), an FDA-approved mesenchymal stromal cell therapy for pediatric steroid-refractory acute graft-versus-host disease, and on additional cell therapy programs for chronic low back pain, heart failure, Duchenne muscular dystrophy and inflammatory or autoimmune diseases.
Recurring company news covers Ryoncil launch and revenue trends, clinical and regulatory developments involving rexlemestrocel-L and Ryoncil label-extension programs, FDA clearances and designations, R&D presentations, technology licensing and platform expansion such as CAR-engineered MSC products, and quarterly cash-flow reporting filed with the Australian Securities Exchange.
Mesoblast (Nasdaq:MESO) received a U.S. FDA Biologics License Application (BLA) filing number and requested modular review for rexlemestrocel-L in preventing life-threatening gastrointestinal bleeding in end-stage heart failure patients with LVADs.
The therapy holds Orphan Drug and RMAT designations, aligning with recent FDA guidance on flexible evidence and CMC requirements for cellular and gene therapies.
Mesoblast (Nasdaq:MESO) drew US$50 million from a five-year, non-dilutive credit facility provided by shareholder and director Dr Gregory George. Mesoblast reported US$122 million in cash at March 30, 2026.
The facility carries fixed 8% interest, a five-year interest-only period, and is secured solely by the Temcell royalty. Proceeds are intended to retire higher-cost NovaQuest debt and remove short-term obligations without encumbering material assets or intellectual property.
Mesoblast (Nasdaq:MESO) reported Ryoncil net revenues of US$30.3m and gross sales US$35.3m for the quarter ended March 31, 2026. Net operating cash spend improved to US$4.1m, cash on hand was US$122m, and first-year Ryoncil sales approach US$100m.
Operationally, Mesoblast achieved patient recruitment for a pivotal Phase 3 CLBP trial, received FDA IND clearance for a registrational Ryoncil trial in DMD, began an SR-aGvHD label-extension trial, and licensed CAR technology for engineered MSCs.
Mesoblast (NASDAQ:MESO) announced its pivotal Phase 3 trial (MSB-DR004) of rexlemestrocel-L for chronic low back pain has met its patient recruitment target. The placebo-controlled study will randomize at least 300 patients to a single intra-discal injection or sham control with 12-month follow-up.
Top-line results are expected in mid-CY2027; a positive readout would support a planned regulatory filing in Q3 CY2027. Rexlemestrocel-L holds FDA RMAT designation for this indication.
Mesoblast (Nasdaq:MESO) acquired an exclusive worldwide license to a patented CAR technology platform to engineer chimeric antigen receptors into mesenchymal stromal cells (MSC) to enhance target specificity and potency.
The license, obtained via acquisition of a startup using ASX ordinary shares, includes Mayo Clinic in-kind support and GMP manufacturing collaboration to advance CAR-MSC products for inflammatory and autoimmune indications including ulcerative colitis, Crohn's disease and lupus nephritis.
Mesoblast (Nasdaq:MESO) received FDA Investigational New Drug (IND) clearance to proceed directly to a registrational trial evaluating Ryoncil (remestemcel-L-rknd) in Duchenne muscular dystrophy (DMD).
The randomized 76‑patient study will enroll boys aged 5–9, with 7 infusions (2x10^6 cells/kg) over nine months and a primary endpoint of time‑to‑stand at nine months.
Mesoblast (Nasdaq:MESO) outlined commercial and R&D advances at its inaugural R&D Day on April 8, 2026, targeting a plan to double net revenues while Ryoncil approaches a US$100 million cumulative net revenue milestone since last year’s launch.
Highlights include Phase 3 CLBP enrollment closing this month, an IRB-cleared adult SR-aGvHD trial with sites activating this quarter, an FDA-cleared IND to proceed to a registrational pediatric DMD trial, and acquisition of a Mayo Clinic–developed patented CAR platform to enhance its MSC products.
Mesoblast (Nasdaq: MESO) announced FDA IND clearance to proceed directly to a registrational trial of Ryoncil® in Duchenne muscular dystrophy (DMD) on April 7, 2026. The randomized trial will enroll 76 patients aged 5–9, dosing 7 infusions of 2 x 106 cells/kg over 9 months, with time-to-stand at nine months as the primary endpoint. Mesoblast cites Ryoncil’s approved pediatric safety profile in steroid-refractory aGvHD, preclinical DMD efficacy, an FDA-approved manufacturing process, and a collaboration with Parent Project Muscular Dystrophy to support enrollment.
Mesoblast (Nasdaq:MESO) reported Ryoncil net sales of US$30.3M for the quarter ended March 31, 2026, with strong February–March demand offsetting January seasonality.
Revenue from Ryoncil in its first year of launch approaches US$100M. The company said Ryoncil strengthens the balance sheet and supports label extension and late‑stage programs. Mesoblast will host an R&D Day on April 8, 2026 with a live webcast.
Mesoblast (Nasdaq: MESO) will hold its inaugural R&D Day on April 8, 2026 in New York City, with a live webcast from 8:00am–11:00am EST.
The program will feature senior leadership and key opinion leaders, discuss corporate strategy, commercialization of Ryoncil, the company’s multi‑billion‑dollar pipeline in inflammatory pain and cardiovascular disease, and unveil new cellular medicine technology. A replay will be posted on the company website.